AUTHORS
Andrew Staron, MD, John Mark L Sloan Jr, MD2, Raphael E. Szalat, MD, PhD3, Natasha J Burke4, Margaux Dockerty, NP5, Deepa M Gopal, MD6, Shabatun M Islam, MD7, Omar K Siddiqi, MD8, Frederick L Ruberg, MD9, Vaishali Sanchorawala, MD10
AFFILIATIONS
1 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
2 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
3 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
4 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
5 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
6 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
7 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
8 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
9 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
10 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
ABSTRACT
Background: Modern plasma cell-directed therapy has markedly improved hematologic outcomes in systemic AL amyloidosis, yet mortality remains driven primarily by cardiac involvement and deep hematologic response does not uniformly translate into cardiac recovery. About one-third of patients achieving hematologic complete response have cardiac non-response or progressive dysfunction. Orthotopic heart transplantation (OHT) is potentially lifesaving in selected patients but published outcome data are limited, with follow-up rarely extending beyond 10 years. We report the largest and longest single-center experience of OHT in this population.
Methods: We retrospectively identified all patients with systemic AL amyloidosis evaluated at our center from 1980?2026 who underwent OHT. Post-transplant all-cause survival was estimated by the Kaplan?Meier method with 95% confidence intervals (CI), censored at last follow-up; one patient who underwent repeat OHT was analyzed from first transplant. Survival was compared by OHT era (before vs after 2010, corresponding to introduction of bortezomib-based regimens) using the log-rank test and Cox regression. OHT eligibility criteria and clone-directed therapy evolved over the study period, reflecting changing practice patterns and therapeutic availability. Patients receiving multiple therapies were counted in more than one post-OHT treatment category.
Results: Of 2,897 patients evaluated, 47 (1.6%) underwent OHT; one patient required repeat OHT after 6 years for cardiac allograft vasculopathy. Four patients underwent concurrent multiorgan transplantation (3 heart-kidney, 1 heart-liver) and 5 required sequential kidney transplantation after OHT (4 for calcineurin inhibitor nephrotoxicity rather than amyloidosis progression). Median age at diagnosis was 56 years (range, 35?66); 40% were female and 13% non-White. Median time from diagnosis to OHT was 0.7 years (range, 0.1?15.7) and median age at OHT was 57 years (range, 38?70). The earliest OHT was performed in 1989; 23 (49%) occurred before 2010 (historical era) and 24 (51%) from 2010 onward (modern era).
Over a median follow-up of 12.2 years, 28 deaths occurred. Median post-OHT survival was 8.3 years (95% CI, 4.5?14.8), with 1-, 5-, 10-, and 15-year survival rates of 87%, 61%, 45%, and 32%, respectively. Median survival was numerically longer in the modern era (8.4 years; 95% CI, 5.6?not reached) than in the historical era (4.6 years; 95% CI, 2.1?13.6), though the difference was not statistically significant (HR 1.78 for historical vs modern; 95% CI, 0.76?4.20; log-rank p=0.18). This comparison was limited by heavy censoring in the modern cohort (16/24 vs 3/23 remained alive). Among 18 deaths with attributable cause, most were due to infections/sepsis (n=7) or complications of OHT or long-term immunosuppression (n=4); only one was attributed to amyloidosis progression.
Most OHT recipients (30/47, 64%) underwent high-dose melphalan with autologous stem cell transplantation (HDM/SCT), including 22 (47%) after OHT. Twenty-two patients (47%) required additional clone-directed therapy post-OHT, generally for immunochemical relapse: most commonly proteasome inhibitors (n=15, 32%, including carfilzomib in one recipient) and daratumumab-based regimens (n=12, 26%), followed by immunomodulatory drugs (n=5, 11%) and oral melphalan (n=2, 4%). Two patients on immunomodulatory drugs subsequently developed acute allograft rejection.
Conclusions: In this nearly four-decade experience, OHT was feasible in carefully selected patients with AL amyloidosis and enabled meaningful long-term survival, with a median post-OHT survival of 8.3 years and 10-year survival of 45%. Outcomes appeared better in the modern era, likely reflecting advances in both transplant medicine and clone-directed therapy, though cohort size and censoring preclude firm conclusions. The frequent need for post-OHT clone-directed therapy underscores the importance of ongoing hematologic surveillance and close collaboration between transplant and hematology teams. Retrospective single-center design, selection bias inherent in transplant eligibility, and incomplete capture of rejection and vasculopathy across the full cohort are limitations of this study. Nonetheless, the findings support broader consideration of OHT in appropriately selected patients and highlight the need for multicenter studies to refine selection criteria and post-OHT management.
DISCLOSURES
Andrew Staron, MD: No relevant conflicts of interest to declare.